Skip to main content Back to Top

What’s the Scoop on Poop in C. difficile Infections?

Broadcast Date: May 18, 2023

 

Subscribe on iTune PodcastsListen on Google PlaySubscribe to Stitcher Podcasts Listen on Spotify Subscribe to TuneIn PodcastsSubscribe to iHeartRadio

Join our experts as they review the current epidemiology of Clostridioides difficile infection (CDI), discuss the risks and complications associated with recurrent CDI, and compare and contrast live biotherapeutic products (LBPs) and traditional fecal microbiota transplantation (FMT).

SPEAKERS

Kelly RevelesKelly R. Reveles, PharmD, PhD, BCPS, BCIDP is an Associate Professor at The University of Texas at Austin College of Pharmacy and an Adjoint Associate Professor at UT Health San Antonio. She received her Doctor of Pharmacy degree from UT Austin in 2010 and her Translational Science PhD degree from UT Austin in 2014. Dr. Reveles’ current research involves clinical and translational sciences focused on the prevention and treatment of Clostridioides difficile infection and the use of microbiome-targeted therapies to prevent infection and other aging-related conditions.

Travis J. Carlson, PharmD, BCIDP is an Assistant Professor at High Point University, Fred Wilson School of Pharmacy in High Point, North Carolina. Dr. Carlson received his PharmD from Drake University and completed his PGY-1 residency at Aurora St. Luke’s Medical Center in Milwaukee, Wisconsin, and his Infectious Diseases Fellowship at Baylor St. Luke’s Medical Center in conjunction with the University of Houston College of Pharmacy in Houston, Texas.

Relevant Financial Relationship Disclosures

The following persons in control of this activity’s content have relevant financial relationships:

Travis J. Carlson – Merck - research grant

Kelly R. Reveles – Ferring Pharmaceuticals - consultant, Speaker's Bureau

All other persons in control of content do not have any relevant financial relationships with an ineligible company.

As defined by the Standards of Integrity and Independence in Accredited Education definition of ineligible company. All relevant financial relationships have been mitigated prior to the CE activity.

Resources

Existing and Emerging Clostridioides difficile Infection Therapies: Importance of Microbiome Restoration

In this Series

What’s the Scoop on Poop in C. difficile Infections?

Are there PROS of PRObiotics over other Microbiome Restoration Products for C. difficile Infections?


The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.
This podcast is provided by ASHP and supported by an educational grant from Ferring Pharmaceuticals Inc.

ASHP Podcasts